Updated: January 28, 2026
How to Help Your Patients Save Money on Sonidegib: A Provider's Guide to Savings Programs
Author
Peter Daggett

- Why Financial Support Matters for Adherence
- Program 1: Sun Pharma Co-Pay Card (Commercial Insurance)
- Program 2: Sun Pharma Patient Assistance Program (Uninsured/Underinsured)
- Program 3: Independent Foundations (Medicare and High-Need Patients)
- Program 4: Medicare Extra Help (Low Income Subsidy)
- Program 5: Insurance Appeals and Tier Exceptions
- Building a Financial Navigation Protocol in Your Practice
- How medfinder Supports Your Patients' Access
- Quick Reference: Savings Programs Summary
Overview
Sonidegib costs ~$14,800/month. This provider guide covers co-pay cards, PAPs, foundation grants, and Medicare savings options to help your laBCC patients afford Odomzo.
Is Sonidegib in stock near you?
Medfinder checks real pharmacy inventory — start a search and we'll find Sonidegib near you.
Prescribing Sonidegib (Odomzo) to a patient with locally advanced basal cell carcinoma is only half the battle. With a list price of approximately $14,800 per month, ensuring your patients can actually afford to start and stay on therapy requires proactive financial navigation. This guide is designed to help oncologists, dermatologists, and their support staff identify and activate every available savings resource for Sonidegib patients in 2026.
Why Financial Support Matters for Adherence
In the BOLT clinical trial, the median treatment duration with Sonidegib was approximately 11 months. However, 34% of patients discontinued due to adverse reactions—and for some, financial toxicity compounds the challenge. Studies consistently show that high patient cost-sharing for oral oncology agents is associated with earlier discontinuation and worse outcomes.
By proactively enrolling patients in financial assistance programs at the time of prescribing—not after they face their first bill—you can dramatically reduce financial barriers to adherence.
Check live stock now.
Program 1: Sun Pharma Co-Pay Card (Commercial Insurance)
The Sun Pharmaceutical Industries co-pay assistance program for Odomzo is the most impactful savings tool for commercially insured patients:
Patient cost: As little as $10 per 30-day supply
Maximum annual benefit: $15,000 per calendar year
Eligibility: Commercially insured patients with valid coverage for Odomzo. Not available for government insurance (Medicare, Medicaid, TRICARE, VA).
Enrollment: www.odomzo.com/savings or call 1-877-636-6961. The card can be activated at www.activatethecard.com/7436.
Practice tip: Have your specialty pharmacy coordinator or medical assistant initiate the co-pay card enrollment on the day of prescribing. Don't wait for the patient to encounter cost barriers first—by then, they may have already delayed their first fill.
Program 2: Sun Pharma Patient Assistance Program (Uninsured/Underinsured)
For patients without insurance or those underinsured (coverage that does not include Odomzo), Sun Pharma offers a Patient Assistance Program (PAP):
Patient cost: Potentially free for eligible patients
How to apply: Contact OdomzoCARE at 1-877-636-6961 or visit www.odomzo.com. The prescriber's office typically needs to submit a PAP application with clinical documentation and financial information.
Documentation needed: Patient's tax documents, insurance status verification, prescriber's signature, and supporting clinical documentation
Practice tip: Screen all new Sonidegib patients for insurance status at the first visit. Patients who are uninsured or whose plan excludes Odomzo should be referred to the PAP immediately.
Program 3: Independent Foundations (Medicare and High-Need Patients)
Manufacturer co-pay cards cannot be used with Medicare. For Medicare beneficiaries and other high-need patients, independent foundations fill the gap:
CancerCare Co-Payment Assistance Foundation (cancercare.org) — provides grants for cancer drug co-pays for Medicare and commercial patients
Patient Advocate Foundation Co-Pay Relief (patientadvocate.org) — disease-specific funds for co-pays and cost-sharing
HealthWell Foundation (healthwellfoundation.org) — disease-specific assistance funds including for Medicare patients
Skin Care Foundation and Skin Cancer Foundation — disease-specific support organizations that may connect patients with financial resources
Practice tip: Keep a current contact list for these foundations at your oncology desk. Fund availability changes frequently (funds open and close); check availability at the time of each new enrollment.
Program 4: Medicare Extra Help (Low Income Subsidy)
For Medicare patients with limited income and resources, the Medicare Extra Help program (also called the Low Income Subsidy, or LIS) can dramatically reduce Part D premiums and cost-sharing. Patients who qualify for full Extra Help pay little to nothing for their medications. Encourage eligible patients to apply through Social Security (1-800-772-1213 or ssa.gov) or to work with your patient navigator on an application.
Program 5: Insurance Appeals and Tier Exceptions
Sonidegib is typically placed on Tier 5 (specialty tier) on most insurance formularies, which carries the highest co-insurance rates. Patients facing high co-insurance should be counseled on their right to:
Request a formulary tier exception on the basis of medical necessity — your office can submit a letter of medical necessity supporting the request
Appeal a PA denial — if prior authorization is denied, file a formal appeal with supporting documentation; request a peer-to-peer review with the insurer's medical director if the appeal is denied
Consider open enrollment alternatives — if a patient has flexible plan selection, a plan with a specialty drug cost cap may significantly reduce their exposure
Found
Rate
on average
Building a Financial Navigation Protocol in Your Practice
Consider implementing a systematic financial navigation process for all Sonidegib patients:
At time of prescribing: Verify insurance, identify eligibility for co-pay card or PAP, initiate enrollment.
PA submission: Submit same day with complete documentation; assign a staff member to track PA status.
PA denial: Immediately file appeal; prepare for peer-to-peer with medical director.
Ongoing: Screen for new financial hardship at each follow-up visit; recheck foundation fund availability quarterly.
How medfinder Supports Your Patients' Access
Financial barriers are just one obstacle. Specialty pharmacy navigation is another. medfinder provides a service that calls pharmacies on patients' behalf to identify which ones can fill their specific prescription. Refer patients to medfinder to reduce the burden of specialty pharmacy navigation. See also our full provider guide on helping patients find Sonidegib.
Quick Reference: Savings Programs Summary
Commercial insurance: Sun Pharma co-pay card → $10/month, up to $15,000/year
Uninsured/underinsured: Sun Pharma PAP → potentially free
Medicare: CancerCare, PAF, HealthWell, Medicare Extra Help (LIS)
Insurance issues: Appeal, peer-to-peer review, tier exception request
Frequently Asked Questions
Commercially insured patients can use the Sun Pharma co-pay card (as low as $10/month, up to $15,000/year). Uninsured or underinsured patients may qualify for the Sun Pharma Patient Assistance Program (potentially free medication). Medicare patients should be referred to foundations like CancerCare, Patient Advocate Foundation, or HealthWell, or to the Medicare Extra Help (LIS) program.
Enrollment can be initiated through OdomzoCARE at 1-877-636-6961 or at www.odomzo.com/savings. The co-pay card can be activated at www.activatethecard.com/7436. Enroll patients at the time of prescribing — don't wait until they face their first bill. Your specialty pharmacy coordinator can often facilitate the enrollment.
No. Federal law prohibits using manufacturer co-pay cards with government insurance programs including Medicare, Medicaid, and TRICARE. For Medicare patients, refer to independent foundations (CancerCare, Patient Advocate Foundation, HealthWell Foundation) or to the Medicare Extra Help (Low Income Subsidy) program through Social Security.
File a formal appeal with complete clinical documentation including the BCC diagnosis, evidence that surgery and/or radiation is not feasible or has failed, and a letter of medical necessity. Request a peer-to-peer review with the insurance company's medical director. While awaiting appeal resolution, explore whether the Sun Pharma PAP can provide a bridge supply.
High patient cost-sharing for oral oncology agents is associated with earlier discontinuation and worse outcomes. In the BOLT trial, the median treatment duration was 11 months, and 34% discontinued due to adverse events. Adding financial barriers makes it even more likely patients will stop therapy early. Proactive enrollment in financial assistance programs at the time of prescribing — not after a billing shock — is associated with better adherence and treatment duration.
Medfinder Editorial Standards
Medfinder's mission is to ensure every patient gets access to the medications they need. We are committed to providing trustworthy, evidence-based information to help you make informed health decisions.
Read our editorial standardsPatients searching for Sonidegib also looked for:
More about Sonidegib
38,004 have already found their meds with Medfinder.
Start your search today.
Your information is private and never shared.





